KRAS and non-small cell lung carcinoma: As the most frequently mutated RAS gene (84%) in human cancer [9, 50], KRAS mutations are associated with a worse prognosis in PDAC (90%), colorectal cancer (50%), non-small cell lung cancer (30%) and other human malignancies [6].